| 000 | 01491 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250511211126.0 | ||
| 264 | 0 | _c19910919 | |
| 008 | 199109s 0 0 eng d | ||
| 022 | _a0264-410X | ||
| 024 | 7 |
_a10.1016/0264-410x(91)90062-b _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiskovsky, E | |
| 245 | 0 | 0 |
_aComparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2 + S antigens. _h[electronic resource] |
| 260 |
_bVaccine _cMay 1991 |
||
| 300 |
_a346-50 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aHepatitis B Antibodies _xbiosynthesis |
| 650 | 0 | 4 |
_aHepatitis B Surface Antigens _xadministration & dosage |
| 650 | 0 | 4 |
_aHepatitis B virus _ximmunology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aProtein Precursors _xadministration & dosage |
| 650 | 0 | 4 | _aSafety |
| 650 | 0 | 4 |
_aVaccines, Synthetic _xadverse effects |
| 650 | 0 | 4 |
_aViral Hepatitis Vaccines _xadverse effects |
| 700 | 1 | _aGershman, K | |
| 700 | 1 | _aClements, M L | |
| 700 | 1 | _aCupps, T | |
| 700 | 1 | _aCalandra, G | |
| 700 | 1 | _aHesley, T | |
| 700 | 1 | _aIoli, V | |
| 700 | 1 | _aEllis, R | |
| 700 | 1 | _aKniskern, P | |
| 700 | 1 | _aMiller, W | |
| 773 | 0 |
_tVaccine _gvol. 9 _gno. 5 _gp. 346-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0264-410x(91)90062-b _zAvailable from publisher's website |
| 999 |
_c1878222 _d1878222 |
||